Editorials

• Debate: The role of percutaneous coronary intervention for left main disease after EXCEL and NOBEL trials

  José M. de la Torre Hernández

  Rev Esp Cardiol. 2021;74:651-4

• Debate: The role of coronary artery bypass grafting for left main disease after EXCEL and NOBLE trials

  Manuel Carnero-Alcázar, Luis Carlos Maroto-Castellanos

  Rev Esp Cardiol. 2021;74:648-50

• Cardiac biomarkers in patients with COVID-19: pragmatic tools in hard times

  Francesco Cannata, Sara Bombace, Giulio G. Stefanini

  Rev Esp Cardiol. 2021;74:566-8

• A new approach to modelling in adult congenital heart disease: artificial intelligence

  Stefan Orwat, Alexandra Arvanitaki, Gerhard-Paul Diller

  Rev Esp Cardiol. 2021;74:573-5

• Coronary bioresorbable vascular scaffolds: requiescant in pace?

  Fernando Alfonso, Javier Cuesta, Fernando Rivero

  Rev Esp Cardiol. 2021;74:569-72

• History of acute coronary syndrome: a common, maybe underestimated, risk factor for heart failure with preserved ejection fraction

  Burkert Pieske, Daniel A. Morris

  Rev Esp Cardiol. 2021;74:480-1

• Comments on the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

  SEC Working Group for the 2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation, Expert Reviewers for the 2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation, SEC Guidelines Committee, SEC Working Group for the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationExpert reviewers for the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevationSEC Guidelines Committee

  Rev Esp Cardiol. 2021;74:482-7

• Comments on the 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease

  SEC Working Group for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease, Expert Reviewers for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease, SEC Guidelines Committee, Working Group for the 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular diseaseExpert reviewers for the ESC guidelines on sports cardiology and exercise in patients with cardiovascular diseaseSEC Guidelines Committee

  Rev Esp Cardiol. 2021;74:488-93

• Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation

  SEC Working Group for the 2020 ESC Guidelines for the Management of Atrial Fibrillation, Expert Reviewers for the 2020 ESC Guidelines for the Management of Atrial Fibrillation, SEC Guidelines CommitteeWorking Group for the 2020 ESC guidelines for the management of atrial fibrillationExpert reviewers for the 2020 ESC guidelines for the management of atrial fibrillationSEC Guidelines Committee

  Rev Esp Cardiol. 2021;74:378-83

• Pulmonary hypertension due to chronic pulmonary thromboembolism. An evolving disease

  Enric Domingo, Santiago Pérez Hoyos, Juan Carlos Grignola

  Rev Esp Cardiol. 2021;74:368-70

• Comments on the 2020 ESC guidelines for the management of adult congenital heart disease

  SEC Working Group for the ESC 2020 Guidelines for the Management of Adult Congenital Heart disease, Expert Reviewers for the ESC Guidelines for the Management of Adult Congenital Heart Disease and SEC Guidelines CommitteeSpanish Society of Cardiology Working Group for the ESC 2020 Guidelines on the Management of DyslipidemiasExpert reviewers for the ESC 2020 Guidelines for the Management of Adult Congenital Heart DiseaseGuidelines Committee of the Spanish Cardiology Society

  Rev Esp Cardiol. 2021;74:371-7

• Adherence to optimal ICD programming: an unresolved issue

  Rafael Peinado Peinado

  Rev Esp Cardiol. 2021;74:286-9

• Significance of potassium alterations. Beyond heart failure

  María G. Crespo-Leiro, Eduardo Barge-Caballero, Javier Muñiz

  Rev Esp Cardiol. 2021;74:293-5

• Why do we need metabolic information in cardiovascular diseases?

  José F. Rodríguez-Palomares

  Rev Esp Cardiol. 2021;74:290-2

• Mind the gap versus filling the gap. The heart beyond specialties

  Isaac Pascual, Francesco Maisano, Carlos A. Mestres

  Rev Esp Cardiol. 2021;74:213-5

• Sudden cardiac death during sports practice. Is one man's meat another man's poison?

  Julián Pérez-Villacastín

  Rev Esp Cardiol. 2021;74:210-2

• Precision medicine in laminopathies: insights from the REDLAMINA registry

  Ramone Eldemire, Matthew R.G. Taylor, Luisa Mestroni

  Rev Esp Cardiol. 2021;74:208-9

• Cardiac microvasculature and adverse remodeling after acute myocardial infarction. New evidence on the use of VEGF as a therapeutic target

  Carlos Zaragoza, Marta Saura, Rafael Ramírez-Carracedo

  Rev Esp Cardiol. 2021;74:124-5

• Atrial fibrillation ablation after the CABANA study: beyond statistical dogma

  Ivo Roca-Luque, José María Tolosana, Josep Brugada

  Rev Esp Cardiol. 2021;74:129-30

• Ultrashort 1- to 3-month double antiplatelet therapy after drug-eluting stent implantation or the conquest of the South Pole

  Imanol Otaegui Irurueta, Bruno García del Blanco, Gerard Martí Aguasca

  Rev Esp Cardiol. 2021;74:126-8